SWOG clinical trial number
Randomized Phase III Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (DMMR) Endometrioid Endometrial Cancer
Testing the addition of the immunotherapy drug, pembrolizumab, to the usual radiation treatment for newly diagnosed early stage high intermediate risk endometrial cancer
Early Therapeutics & Rare Cancers
Eligibility Criteria Expand/Collapse
Please review protocol eligibility criteria on the CTSU website (http://www.ctsu.org/) for more information.